
Bayer to Present 7 New Analyses on Finerenone’s Benefits in High-Risk Heart Failure Patients
Bayer has announced new subgroup analyses from the Phase III FINEARTS-HF trial, which evaluated the efficacy of finerenone (Kerendia™) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40% or higher. These findings will be…